Updates are available Correction dated 2022-06-06
Click to view Correction: https://doi.org/10.1007/s00262-022-03233-1
-
Authors
Zangari, Brendan
Tsuji, Takemasa
Matsuzaki, Junko
Mohammadpour, Hemn
Eppolito, Cheryl
Battaglia, Sebastiano
Ito, Fumito
Chodon, Thinle
Koya, Richard
Robert McGray, A. J.
Odunsi, Kunle http://orcid.org/0000-0002-4444-7651
-
Funding
Funding for this research was provided by:
National Cancer Institute (P50CA159981-01A1, U01CA233085, P30CA016056, P30CA014599)
- License Information
-
More Information
Article History
Received: 24 November 2021
Accepted: 24 March 2022
First Online: 23 April 2022
Change Date: 6 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-022-03233-1
Declarations
:
: JM, TT, TC and KO are inventors of a patent application by Roswell Park Comprehensive Cancer Center regarding the TCR genes. KO and RK are cofounders of Tactiva Therapeutics and receives research support from AstraZeneca and Tesaro.
: Animal experiments were carried out with protocols approved by the Institute of Animal Care and Use Committee at the Roswell Park Comprehensive Cancer Center. PBMC were collected as byproducts of apheresis of platelets from consenting donors.
